To evaluate whether therapy with sildenafil citrate prolongs gestation in women with preeclampsia.
RESULTS:
From June 2013 to October 2015, 50 patients were randomized to each group. Pregnancy duration was on average 4 days longer (14.4 days, 95% confidence interval [CI] 12.5-16.6 days compared with 10.4 days, 95% CI 8.4-12.3 days, P5.008) and percent reduction in pulsatility indices of uterine and umbilical arteries higher (22.5% and 18.5%, compared with placebo 2.1% and 2.5%, P,.001) for patients treated with sildenafil compared with placebo. Maternal blood pressure before and 24 hours after randomization was lower with sildenafil (sildenafil: 100.365.6 mm Hg compared with 116.465.1 mm Hg, P,.05; placebo: 110.666.2 mm Hg compared with 114.766.5 mm Hg, P5.21). There was no difference in perinatal morbidity, mortality, or adverse effects between groups.
CONCLUSION: Therapy with sildenafil citrate was associated with pregnancy prolongation of approximately 4 days compared with placebo in women with preeclampsia.
CLINICAL TRIAL REGISTRATION:
Brazilian Registry of Clinical Trials, www.ensaiosclinicos.gov.br, RBR-8qj4p5. P revious studies have shown that expectant management of preeclampsia in the context of extreme prematurity may improve perinatal outcomes. [1] [2] [3] Indeed, it has been estimated that for each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is a nonlinear corresponding gain of 1% in fetal survival. 4 The etiology and pathophysiology of preeclampsia have not been clearly established; impaired immunologic adaptation and genetic incompatibility seem to be involved in deficient trophoblastic implantation. 5, 6 Placental hypoxia and endothelial dysfunction may lead to preeclampsia through an exacerbated systemic inflammatory reaction. 7 Increased placental expression and secretion of soluble fms-like tyrosine kinase 1 appear to play a central role in the pathogenesis of preeclampsia. The soluble fms-like tyrosine kinase 1 antagonizes the proangiogenic biologic activity of circulating vascular endothelial growth factor and placental growth factor, leading to a failure of nitric oxide signaling to smooth muscle.
Nitric oxide is a potent vasodilator, particularly for the venules, besides being an inhibitor of platelet aggregation. 8 During pregnancy, nitric oxide is synthesized in in utero placental tissues and endothelial cells, helping to maintain low vascular resistance in the utero-and fetoplacental circulations. [9] [10] [11] Phosphodiesterase metabolizes cyclic guanosine monophosphate; therefore, phosphodiesterase type 5 inhibition leads to cyclic guanosine monophosphate increase with associated vasodilation, independently of nitric oxide. Therefore, phosphodiesterase type 5 inhibitors have the potential to achieve similar therapeutic goals when compared with nitric oxide. A potential advantage of phosphodiesterase type 5 inhibitors is that they may overcome the main limitation to nitric oxide use in pregnancy, which is tolerance and headaches. The most studied phosphodiesterase type 5 inhibitor is sildenafil citrate, which has previously shown promising outcomes both in vitro 12 and in animal studies. 13, 14 In this study, we evaluated the use of sildenafil citrate for the treatment of singleton pregnancies complicated by preeclampsia. We hypothesized that the potential increase in in utero placental and fetoplacental blood flow with the use of sildenafil citrate may be associated with pregnancy prolongation (the primary study outcome) and improved maternal and perinatal outcomes.
MATERIALS AND METHODS
We conducted a randomized, double-blind, placebocontrolled trial designed to evaluate the efficacy and safety of sildenafil citrate in preterm pregnancies complicated by preeclampsia. The study was conducted at the high-risk obstetric unit of the University Hospital of Federal University of Santa Catarina, Florianopolis, Brazil. The study was approved the hospital ethics committee (platform Brazil/SISNEP, study number 01716812.9.0000.0121) according to the 2008 Helsinki Declaration. All patients signed a written informed consent and all patients were at least 18 years old at the time of enrollment.
Preeclampsia was defined as development of hypertension after 20 weeks of gestation (diastolic blood pressure 90 mm Hg or greater, systolic blood pressure 140 mm Hg or greater, or both) with associated proteinuria (greater than 300 mg in 24 hours) in a patient with previous normal blood pressure. Blood pressure criteria had to be met in two measurements taken at least 4 hours apart.
Inclusion criteria were singleton pregnancies admitted to the high-risk obstetric unit or a period of at least 24 hours (to confirm the diagnosis of preeclampsia and absence of exclusion criteria) and gestational age between 24 and 33 weeks calculated from the date of the last menstrual period and confirmed by first-trimester ultrasonography. The patients remained in the hospital until delivery.
Exclusion criteria were a history of hypertension, chronic disorders such as diabetes, fetal malformations, or maternal or fetal comorbidities or both that could lead to early pregnancy interruption (eg, intrauterine fetal demise; hemolysis, elevated liver enzymes, and low platelet count [HELLP] syndrome; severe renal insufficiency; premonitory symptoms of eclampsia; reversed diastolic blood flow in the umbilical artery; reversal of flow during atrial contraction in the ductus venosus; amniotic fluid index 5 cm or less; or a biophysical profile less than 6/10). Additional exclusion criteria were use of erythromycin, ketoconazole, itraconazole, antiretroviral agents, or any other medication that could interact with sildenafil. Patients using antihypertensive medications other than a-methyldopa were also excluded.
Patients were assigned to either the treatment or the placebo group based on blocked randomization (blocks of five) with sealed and numbered opaque envelopes. The process of randomization and distribution of envelopes was coordinated by the pharmacy service of the University Hospital. Study investigators, attending physicians, ultrasonographers, neonatologists, and patients were blinded regarding allocation to placebo or sildenafil groups until the end of the study. Oral sildenafil citrate at 50 mg or identical placebo capsules were dispensed by the hospital pharmacy. Medication was given was given every 8 hours (6 AM, 2 PM, 10 PM). Sildenafil citrate dose was chosen based on safety profile and favorable results from prior studies. [15] [16] [17] Doppler velocimetry of the uterine, umbilical, and middle cerebral arteries was performed using a Toshiba Xario SSA_660A scanner equipped with a 3.5-MHz convex transducer. Patients were examined in semiFowler position during a period of absent fetal movements, breathing, or both 1-4 hours after administration of the study drug. Blood flow was interrogated on the ascending branches of the right and left uterine arteries at the point of apparent crossing with the external iliac arteries. Umbilical blood flow was interrogated on a free loop of umbilical cord. The middle cerebral artery was interrogated on an axial section of the fetal brain at the level of the circle of Willis.
Doppler sample gate was adjusted according to vessel diameter. The insonation angle was kept as close to zero as possible. Angle correction was not used. Each sequence of measurements was obtained in triplicate during each examination and the results
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averaged. The pulsatility index was automatically calculated by the equipment. The same operator performed all Doppler examinations. Comparison between Doppler measurements was performed between the examination performed on the day before randomization and the examination performed 24 hours after the beginning of treatment with sildenafil citrate or placebo.
Maternal arterial blood pressure was measured using a mercury column sphygmomanometer, always on the left arm, with the patient sitting and with the fourth Korotkoff's sound used to determine diastolic blood pressure. Blood pressure measurements were obtained routinely every 4 hours (in standard times). Mean arterial pressure (MAP) (diastolic blood pressure+1/3 [systolic pressure-diastolic pressure]) was used for comparisons between the average MAP 24 hours before and 24 hours after randomization.
Fetal growth restriction was defined as an estimated fetal weight less than the 10th percentile. 18 Most patients received a-methyldopa (500-1,500 mg per day) with an additional b-blocker agent (10-30 mg pindolol per day) as required for clinical management. Intravenous hydralazine (5-30 mg) was used when a rapid action antihypertensive medication was deemed necessary. Betamethasone (two doses of 12 mg intramuscularly 24 hours apart) was prescribed only in cases of anticipated delivery within 72 hours.
Decision to deliver the fetus by the perinatology team was based on local criteria. Before 34 weeks of gestation, our protocol is to deliver only in case of severely abnormal antenatal testing (reverse diastolic blood flow in the umbilical artery, reversal of flow during atrial contraction in the ductus venosus, amniotic fluid index 5 or less, or biophysical profile less than 6/10) or for maternal indications (failure to achieve satisfactory blood pressure control after reaching maximum dosage of antihypertensive agents, progressive deterioration of renal function with creatinine greater than 2 mg/dL, eclampsia, neurologic impairment, or HELLP syndrome). After 34 weeks of gestation, delivery was also indicated in case of diastolic blood pressure 110 mm Hg or greater, systolic blood pressure 160 mm Hg or greater, proteinuria greater than 5 g in 24 hours, or all of these. Magnesium sulfate was administered when evident premonitory signs of eclampsia were present or when delivery was indicated (loading dose56 g intravenously, maintenance dose52 g per hour as a continuous intravenous infusion).
Perinatal outcome measures included birth weight and Apgar scores. All live neonates underwent a scheduled consultation 30-40 days after hospital discharge.
Independent data and safety and monitoring were provided the hospital's Division of Pharmacovigilance. Results were monitored after every 20 deliveries. It was preestablished that the study would be interrupted in case outcomes with sildenafil citrate were significantly worse than those with placebo. The Division of Pharmacovigilance was also responsible for the surveillance for maternal, fetal, or both side effects. Medication compliance was ensured by direct observation of medication intake.
The power analysis estimated that, to detect a mean difference of 5 days in pregnancy duration with 90% power and a of 0.05, 43 patients in each group would have to be enrolled. 2, 15 Fifty patients were enrolled in each group to compensate for possible noncompliance or withdrawals.
Data were analyzed according to intention to treat. Categorical variables were compared by x 2 test or Fisher exact test for small samples (less than five). Continuous variables were compared by Student t test. A P value ,.05 was considered significant. The pulsatility indices of the uterine, umbilical, and middle cerebral arteries were normalized for gestational age using Z-scores. Paired Z-scores were then compared using analysis of variance. Statistical analysis was performed using SPSS 20.0 for Windows.
RESULTS
From June 2013 and October 2015, 100 patients were invited to participate in the study. Four patients asked to withdraw from the study before delivery (two in each group) as a result of feeling insecure about participating in a research project with a placebo. Another three patients, one in the sildenafil citrate group with severe headache and facial flushing and two in the placebo group with severe headaches, discontinued treatment. These seven women consented that their data be analyzed according to intention-to-treat (Fig. 1) . Baseline characteristics were not significantly different between the two groups ( Table 1) . There was no difference in the severity of preeclampsia. All fetuses were delivered based on clinical criteria shown in Table 2 .
Time interval between randomization and delivery was on average 4.01 days longer for the patients treated with sildenafil citrate when compared with placebo (14.4 Resistance to blood flow in the uterine and umbilical arteries was significantly lower in patients treated with sildenafil citrate. In the sildenafil group, 22.5% experienced a reduction in the uterine artery pulsatility index compared with 2.1% in the placebo group (P,.001), and 18.5% in the sildenafil group experienced a reduction in the umbilical artery pulsatility index compared with 2.5% in the placebo group (P,.001). There was no difference in resistance to blood flow in the middle cerebral artery (Table 3) .
During the first 24 hours of study, MAP was significantly lower after administration of sildenafil citrate (100.365.6 mm Hg after sildenafil citrate compared with 116.465.1 mm Hg before sildenafil citrate, P,.05). No significant reduction in MAP was observed after administration of placebo (110.666.2 mm Hg after placebo compared with 114.766.5 before placebo, P5.21).
The medication was well tolerated. There was no difference in the incidence of adverse events between the groups (Table 4) . Only three patients suspended the medication as a result of possible side effects (severe headache): one in the study group and two in the control group. There were no differences in neonatal outcomes between the two groups ( Table 5 ).
DISCUSSION
Our study shows that sildenafil citrate given to women with preeclampsia with a severe feature at an oral dose of 50 mg every 8 hours allowed the prolongation of pregnancy by an average of 4 days. We speculate that this prolongation may be the result of better control of blood pressure, improvement of maternal and fetal blood flow, or a combination thereof. Data are n (%) unless otherwise specified. Analysis based on intention to treat. * Creatinine greater than 2 mg/dL, thrombocytopenia, or elevated liver enzymes. † Premonitory symptoms eclampsia. ‡ Failure to achieve satisfactory blood pressure control after reaching maximum dosage of antihypertensive agents. Copyright Ó by The American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc.
Prolongation of pregnancy in the current study was similar to that observed by studies comparing aggressive and expectant management of preeclampsia. 2, 19 The study of Samangaia et al, 15 for example, showed that sildenafil was effective in decreasing maternal blood pressure but not prolonging pregnancy. The difference between that study and ours may be explained by the smaller number of cases in their study, later start of treatment (31.4 against 29.1 weeks of gestation), lower dose (20 mg three times a day), and possibly a difference in stopping criteria, which tends to be uniform in a single center such as ours.
Our results also showed that sildenafil citrate administration reduces resistance to blood flow in the uteroplacental and fetoplacental circulations and is associated with a decrease in maternal mean blood pressure and that these changes are not associated with concomitant changes in the resistance to blood flow in fetal cerebral vessels. The decrease in uterine and umbilical artery pulsatility indices with the use of sildenafil has been previously reported in case reports 20, 21 as well as in one randomized double-blind, placebo-controlled study. 22 All previous studies confirm that the pulsatility index of the middle cerebral artery remains unaltered after nitric oxide donor administration, suggesting that the control of fetal cerebral arterial vascular tone is independent of external nitric oxide supply. 10, 11, 23, 24 Reduction in maternal MAP, without compromising uterine artery blood flow, provides reassurance that sildenafil may be useful as an antihypertensive drug in the context of placental vascular insufficiency. Although we identified no differences between study groups in neonatal outcomes, this could be the result of a lack of power given the small number of cases, the late start of medication, or both. It is well known that pathologic changes involving the uteroplacental circulation begin well before clinical manifestation of disease. 25 Therefore, treatment may have to begin earlier to allow earlier improvement in in utero and fetoplacental blood flow and to avoid endothelial dysfunction and the release of inflammatory factors.
Based on its mechanism of action in the endothelium, sildenafil citrated can be compared with soluble fms-like tyrosine apheresis, 26 statins, 27 and relaxin 28 for the treatment of preeclampsia. The benefit of sildenafil therapy would likely be in cost, access, and bypassing the counterproductive risks of nitric oxide donors, which induce peroxynitrite and led to vasoconstriction instead of vasodilation. 29 These results, combined with the results of other studies, 30 are promising. However, studies with a larger number of patients and an earlier start of medication are required. Future evaluation of other phosphodiesterase type 5 inhibitors, particularly if the medication can be safely started earlier and used for a longer period of time, may prove beneficial in the treatment of patients affected by preeclampsia.
